Free Trial

Galera Therapeutics (GRTX) Competitors

$0.11
0.00 (0.00%)
(As of 06/7/2024 ET)

GRTX vs. LCI, TXMD, RNXT, APLM, ITRM, ONCT, VIRX, COCP, INDP, and BCTX

Should you be buying Galera Therapeutics stock or one of its competitors? The main competitors of Galera Therapeutics include Lannett (LCI), TherapeuticsMD (TXMD), RenovoRx (RNXT), Apollomics (APLM), Iterum Therapeutics (ITRM), Oncternal Therapeutics (ONCT), Viracta Therapeutics (VIRX), Cocrystal Pharma (COCP), Indaptus Therapeutics (INDP), and BriaCell Therapeutics (BCTX). These companies are all part of the "pharmaceutical preparations" industry.

Galera Therapeutics vs.

Galera Therapeutics (NASDAQ:GRTX) and Lannett (NYSE:LCI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations, community ranking and media sentiment.

Galera Therapeutics has higher earnings, but lower revenue than Lannett. Galera Therapeutics is trading at a lower price-to-earnings ratio than Lannett, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galera TherapeuticsN/AN/A-$59.08M-$0.99-0.11
Lannett$340.58M0.00-$231.62M-$18.88N/A

Lannett received 410 more outperform votes than Galera Therapeutics when rated by MarketBeat users. Likewise, 59.59% of users gave Lannett an outperform vote while only 54.35% of users gave Galera Therapeutics an outperform vote.

CompanyUnderperformOutperform
Galera TherapeuticsOutperform Votes
50
54.35%
Underperform Votes
42
45.65%
LannettOutperform Votes
460
59.59%
Underperform Votes
312
40.41%

Galera Therapeutics has a net margin of 0.00% compared to Lannett's net margin of -62.40%.

Company Net Margins Return on Equity Return on Assets
Galera TherapeuticsN/A N/A -138.81%
Lannett -62.40%N/A -13.39%

In the previous week, Galera Therapeutics' average media sentiment score of 0.00 equaled Lannett'saverage media sentiment score.

Company Overall Sentiment
Galera Therapeutics Neutral
Lannett Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galera Therapeutics
1 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.75
Lannett
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Galera Therapeutics has a beta of 2.04, indicating that its share price is 104% more volatile than the S&P 500. Comparatively, Lannett has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500.

50.8% of Galera Therapeutics shares are held by institutional investors. Comparatively, 40.3% of Lannett shares are held by institutional investors. 6.9% of Galera Therapeutics shares are held by company insiders. Comparatively, 13.1% of Lannett shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Lannett beats Galera Therapeutics on 6 of the 11 factors compared between the two stocks.

Get Galera Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GRTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GRTX vs. The Competition

MetricGalera TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$6.12M$6.97B$5.22B$8.20B
Dividend YieldN/A2.66%2.73%4.04%
P/E Ratio-0.1111.04120.0414.65
Price / SalesN/A295.512,432.4578.07
Price / CashN/A32.9935.2531.17
Price / Book-0.055.654.964.32
Net Income-$59.08M$147.15M$110.34M$216.21M
7 Day Performance-49.33%-2.05%-1.05%-1.43%
1 Month Performance-38.76%-2.37%-0.61%-0.59%
1 Year Performance-96.38%-5.74%2.92%3.58%

Galera Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LCI
Lannett
0 of 5 stars
N/AN/AN/A$7.38M$340.58M-0.04810Analyst Forecast
High Trading Volume
TXMD
TherapeuticsMD
0 of 5 stars
$2.17
-1.8%
N/A-47.1%$25.02M$1.30M0.001Analyst Forecast
News Coverage
RNXT
RenovoRx
0.9902 of 5 stars
$1.04
-9.6%
$8.50
+717.3%
-48.5%$24.91MN/A-1.4410Gap Down
APLM
Apollomics
1.6244 of 5 stars
$0.27
-2.6%
$2.00
+627.8%
-96.1%$24.60M$1.22M0.0045Gap Down
ITRM
Iterum Therapeutics
0.5681 of 5 stars
$1.48
+3.5%
$6.00
+305.4%
+22.1%$24.51MN/A-0.5614Gap Up
ONCT
Oncternal Therapeutics
2.2231 of 5 stars
$8.25
-6.0%
$28.33
+243.4%
+35.8%$24.42M$790,000.00-0.6727Analyst Forecast
Gap Down
VIRX
Viracta Therapeutics
1.2447 of 5 stars
$0.60
-16.4%
$6.50
+983.3%
-59.7%$23.56MN/A-0.4940Positive News
Gap Down
COCP
Cocrystal Pharma
2.173 of 5 stars
$2.31
-0.4%
$10.00
+332.9%
-3.1%$23.49MN/A-1.3312News Coverage
Positive News
INDP
Indaptus Therapeutics
2.352 of 5 stars
$2.75
-1.8%
$12.00
+336.4%
+25.6%$23.49MN/A-1.547
BCTX
BriaCell Therapeutics
1.6986 of 5 stars
$1.46
-4.4%
$18.00
+1,130.7%
-77.4%$23.37MN/A-0.8716Upcoming Earnings
Analyst Forecast

Related Companies and Tools

This page (NASDAQ:GRTX) was last updated on 6/8/2024 by MarketBeat.com Staff

From Our Partners